Study S002011

PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05390892
Acronym: PRECIDENTD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 6000
Start: 2022-09-26
Primary completion: 2029-03-01
Lead sponsor: Brigham and Women's Hospital
Conditions: Type2Diabetes; ASCVD
Interventions: DRUG:SGLT2 inhibitor; DRUG:GLP-1 receptor agonist
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Total (first and recurrent) cardiovascular, kidney, and death events [Through study completion, with an average follow up of approximately 3 years]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002960	Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial. Wexler DJ, American heart journal	2026	Randomized trial	PMID 41456635 DOI	cites ClinicalTrials.gov:NCT05390892; registry reference DERIVED:41456635